Related Experiment Video
Updated: Jun 27, 2026

07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
Malaria eradication: the economic, financial and institutional challenge
Anne Mills1, Yoel Lubell, Kara Hanson
1Health Economics and Financing Programme, Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. Anne.Mills@lshtm.ac.uk
Malaria Journal
|December 19, 2008
Summary
Achieving malaria eradication faces significant economic, financial, and institutional hurdles. While benefits generally outweigh costs, challenges in scaling up control and strengthening health systems require further research for effective policies.
Area of Science:
- Global Health
- Health Economics
- Public Policy
Background:
- Malaria eradication efforts have historically encountered substantial economic, financial, and institutional obstacles.
- Previous eradication campaigns, particularly in resource-limited settings, provide valuable lessons on implementation difficulties.
Purpose of the Study:
- To review and synthesize evidence on the economic, financial, and institutional challenges of malaria eradication.
- To analyze recent literature on scaling up malaria control and health system strengthening in the context of renewed eradication calls.
Main Methods:
- Literature review of historical malaria eradication efforts.
- Analysis of recent studies on malaria control scale-up and health system challenges.
- Synthesis of economic, financial, and institutional evidence.
Main Results:
- Economic analyses indicate that the benefits of malaria control generally exceed costs, though cost-benefit analyses for eradication versus long-term control are limited.
- Financial cost estimates for malaria control and eradication are scarce and variable, with recent estimates for high coverage being several dollars per capita.
- Key institutional challenges include legal limitations, the effectiveness of local structures, and political sustainability at national and global levels.
Conclusions:
- Renewed calls for malaria eradication and intensified control must address the identified economic, financial, and institutional challenges.
- A comprehensive research agenda is proposed, focusing on allocative efficiency, economic development links, intervention costs, coverage extension, policy implementation, and financing.
Related Concept Videos
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Symbiosis
Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

